Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline Review, H1 2020’, provides an overview of the Neurofibromatoses Type I (Von Recklinghausen’s Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type I (Von Recklinghausen’s Disease)

– The report reviews pipeline therapeutics for Neurofibromatoses Type I (Von Recklinghausen’s Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Neurofibromatoses Type I (Von Recklinghausen’s Disease) therapeutics and enlists all their major and minor projects

– The report assesses Neurofibromatoses Type I (Von Recklinghausen’s Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Neurofibromatoses Type I (Von Recklinghausen’s Disease)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen’s Disease)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Neurofibromatoses Type I (Von Recklinghausen’s Disease) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AstraZeneca Plc

NFlection Therapeutics Inc

Pfizer Inc

SpringWorks Therapeutics Inc

Vyriad Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Overview

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Companies Involved in Therapeutics Development

AstraZeneca Plc

NFlection Therapeutics Inc

Pfizer Inc

SpringWorks Therapeutics Inc

Vyriad Inc

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Drug Profiles

binimetinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mirdametinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NFX-179 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oncolytic Virus to Target CD46 and SLC5A5 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selumetinib sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sirolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Neurofibromatoses Type I - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Dormant Projects

Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Product Development Milestones

Featured News & Press Releases

Apr 14, 2020: KOSELUGO (selumetinib) approved for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas in pediatric patients, available from Onco360

Apr 13, 2020: FDA approves AstraZeneca's Koselugo to treat rare genetic disorder

Apr 10, 2020: FDA Approves First Ever Treatment for Neurofibromatosis

Mar 18, 2020: In NIH trial, selumetinib shrinks tumors, provides clinical benefit for children with NF1

Nov 15, 2019: FDA grants priority review to tumour drug selumetinib

Oct 28, 2019: Selumetinib shows clinical benefit in adult patients with Neurofibromatosis Type 1-Associated Plexiform Neurofibromas

Oct 25, 2019: SpringWorks starts Phase IIb trial of mirdametinib in NF1-PN

Jul 30, 2019: European Commission grants Orphan Drug Designation for SpringWorks Therapeutics’ MEK Inhibitor, Mirdametinib, for the treatment of Neurofibromatosis Type 1

Jun 03, 2019: SpringWorks Therapeutics Announces FDA Fast Track Designation for PD-0325901 for the Treatment of a Severe Form of Neurofibromatosis Type 1

Apr 01, 2019: FDA grants AstraZeneca-Merck’s selumetinib breakthrough therapy designation

Dec 10, 2012: Study Identifies Targeted Molecular Therapy For Untreatable NF1 Tumors

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline by AstraZeneca Plc, H1 2020

Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline by NFlection Therapeutics Inc, H1 2020

Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline by Pfizer Inc, H1 2020

Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline by SpringWorks Therapeutics Inc, H1 2020

Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Pipeline by Vyriad Inc, H1 2020

Neurofibromatoses Type I (Von Recklinghausen’s Disease) – Dormant Projects, H1 2020

List of Figures

List of Figures

Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports